Tag: prevalence

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

NEWARK, Del., June 2, 2026 /PRNewswire/ -- The Demand for Compounding Pharmacies in USA is projected to grow from USD 6.04 billion in 2026 to...

As chronic disease, GLP-1 adoption, and food for health reshape American healthcare, Kroger Health gathers leaders to explore the grocery store's emerging role as...

AQUIPTA® (atogepant) is now approved in the European Union for the acute treatment of migraine in adults, with or without aura, and for the...

Jon Keyser Appointed Interim Chief Executive OfficerMESA, Ariz., June 1, 2026 /PRNewswire/ -- Verra Mobility Corporation (NASDAQ: VRRM), a leading provider of smart mobility...

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025...

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025...

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025...

The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.

The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

iPETcertum™ by Claritas, Developed with Cutting-Edge Technology for Enhancement, Automated Segmentation and Accurate Quantification in PET, PET-CT/MRI Scan

The market for IBAT inhibitors is projected to experience significant growth in the near future, fueled by the rising incidence of genetic disorders, a...